OOIR: Observatory of International Research

Papers

(The TQCC of JAMA Neurology is 20. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Diplopia and Ptosis in an Older Woman	516
Somebody to Love	493
Optimizing the Time Course of Risks and Benefits of Acute Dual Antiplatelet Therapy for Stroke Prevention	381
Itching Frequency and Neuroanatomic Correlates in Frontotemporal Lobar Degeneration	380
Risk of Dementia in Individuals With Emergency Department Visits or Hospitalizations Due to Cannabis	235
Error in Author Name	230
Early Posttraumatic Seizures—Putting Things in Perspective	229
A Call to Action to Address Sex Differences in Alzheimer Disease Clinical Trials	226
Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation	220
Origin of Transthyretin in Cerebral Amyloid Angiopathy	217
Ghrelin for Neuroprotection in Post–Cardiac Arrest Coma	212
Rizatriptan vs Placebo for Attacks of Vestibular Migraine	211
Equipping AI for Unbiased and Inclusive Neurology	211
Early Access to First-Seizure Clinics, Subsequent Outcomes, and Factors Associated With Attendance	211
Automated Imaging Differentiation for Parkinsonism	210
Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation	191
Substantia Nigra Pathology, Contact Sports Play, and Parkinsonism in Chronic Traumatic Encephalopathy	190
Alternate Hemibody Hyperkinetic and Hypokinetic Movement Disorders Due to Strategic Lesions in Cerebral Toxoplasmosis	181
Magnetic Resonance Imaging Features of Tropical Candidal Meningoencephalitis	179
Reinterpreting Clinical Trials in Children With Multiple Sclerosis Using a Bayesian Approach	175
JAMA Neurology	161
Thrombolysis With Tenecteplase for Minor Disabling Stroke	157
Isosorbide Mononitrate and Cilostazol Treatment in Patients With Symptomatic Cerebral Small Vessel Disease	155
Effect of Neprilysin Inhibition on Alzheimer Disease Plasma Biomarkers	154
JAMA Neurology	151

Is It Really Itching?	144
The Neurologist’s Imperative in Brain Death	144
Teleneurorehabilitation and Motor and Nonmotor Symptoms and Quality of Life in Parkinson Disease	141
External Carotid Artery Angioplasty Based on Ultrahigh-Resolution Photon-Counting CTA	135
Time to Change the Current Clinical Classification of Multiple Sclerosis?	134
Anticoagulation and Antiplatelet Therapy in Patients With Atrial Fibrillation and Atherosclerosis	132
Time From Hospital Arrival Until Endovascular Thrombectomy and Patient-Reported Outcomes in Acute Ischemic Stroke	126
Highly Effective Therapies as First-Line Treatment for Pediatric-Onset Multiple Sclerosis	124
Functional Outcomes in Conservatively vs Surgically Treated Cerebellar Infarcts	120
Alzheimer Disease as a Clinical-Biological Construct—An International Working Group Recommendation	119
Do Neurologists Need a Goldwater Rule?	116
Error in Abstract	116
Disentangling Workflow Paradigms and Treatment Decision-making in Acute Ischemic Stroke	109
Histologic Anatomy of Neurocysticercosis	106
Error in Figure	105
Error in Additional Contributions	104
Spontaneous AICA Dissection Presenting With Isolated Audiovestibular Loss	102
Error in Figure	100
Association of Cardiovascular Events With Spouse’s Subsequent Dementia	99
Functional Seizures—A Critical Comorbidity Overlooked in Epilepsy Research—Reply	99
Is It Really Itching?—Reply	99
Sleep Recording for the Diagnosis and Treatment of Paraplegia	99
Spinal Cerebrospinal Fluid Leak Mimicking a Cerebellopontine Angle Tumor	99
JAMA Neurology	98
Endovascular Stroke Thrombectomy for Patients With Large Ischemic Core	98
β-Amyloid Positron Emission Tomography Use Across Medicare Administrative Contractor Regions	98
Retinal Hemorrhage Associated with Human Granulocytic Anaplasmosis	95
Posttreatment Amyloid Levels and Clinical Outcomes Following Donanemab for Early Symptomatic Alzheimer Disease	94
Seizure Frequency Trends Over Time in Treatment-Resistant Focal Epilepsy	94
Tackling the Unmet Therapeutic Needs in Nonsurgical Treatments for Epilepsy	92
Interhemispheric Bullet Migration—A Surgical Dilemma	91
N-Acetylcysteine for Hereditary Cystatin C Amyloid Angiopathy	89
Prourokinase vs Standard Care for Patients With Mild Ischemic Stroke	88
Risk Factors Associated With Late-Onset Epilepsy in Dementia and Mild Cognitive Impairment	88
Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum	87
Noncontrast Computed Tomography vs Computed Tomography Perfusion or Magnetic Resonance Imaging Selection in Late Presentation of Stroke With Large-Vessel Occlusion	86
Wind Swirl Pattern on Density Spectral Array in Anti-GABAB Receptor Encephalitis With Amnestic Seizures	85
Contribution of Somatic Ras/Raf/Mitogen-Activated Protein Kinase Variants in the Hippocampus in Drug-Resistant Mesial Temporal Lobe Epilepsy	85
Intra-Arterial Tenecteplase After Successful Reperfusion in Large Vessel Occlusion Stroke	84
Role of the X Chromosome in Alzheimer Disease Genetics	82
GLP-1RA and SGLT2i Medications for Type 2 Diabetes and Alzheimer Disease and Related Dementias	82
Neuronally Derived Extracellular Vesicle α-Synuclein as a Serum Biomarker for Individuals at Risk of Developing Parkinson Disease	80
Current and Future Roles of Chimeric Antigen Receptor T-Cell Therapy in Neurology	80
JAMA Neurology	78
Error in Text	77
JAMA Neurology	77
Perceived CTE and Suicidality—Is Perception Reality?	76
Acute Myelopathy in a Man With Cutaneous Papules	76
Error in Key for Figure 3	75
Peripheral-Type Facial Paralysis and Unilateral Hemisphere Hemorrhage	75

Error in Figures	75
Behavioral Compared With Drug Therapy for Overactive Bladder Symptoms in Parkinson Disease	75
Ongoing Challenges in the Diagnosis of Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease	73
A Rare Neurological Presentation of Kikuchi-Fujimoto Disease	72
The New Era of Automated Electroencephalogram Interpretation	71
AI Devices in Neurology—Moving From Diagnosis to Prognosis	71
Minimally Invasive Surgery vs Medical Management Alone for Intracerebral Hemorrhage	70
Magnetic Resonance Imaging Features of GABA-A Receptor Antibody-Mediated Encephalitis	69
Emerging Cerebrospinal Fluid Biomarkers of Disease Activity and Progression in Multiple Sclerosis	69
A 62-Year-Old Man With Progressive Limb Weakness, Involuntary Movements, and HyperCKemia	68
Symptomatic Intracranial Hemorrhage With Tenecteplase vs Alteplase in Patients With Acute Ischemic Stroke	68
Comparison of Perinatal Outcomes for Women With and Without Epilepsy	68
Prognostic Factors for Multiple Sclerosis Symptoms in Radiologically Isolated Syndrome	68
Functional Impairment in Individuals With Prodromal or Unrecognized Parkinson Disease	68
Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis	66
“The Triage of Privilege” Factual Concerns	66
The Semont-Plus Maneuver or the Epley Maneuver in Posterior Canal Benign Paroxysmal Positional Vertigo	66
Expanding Clinical Spectrum of Anti-GQ1b Antibody Syndrome	65
Bibrachial Amyotrophy Due to Spontaneous Spinal Cerebrospinal Fluid Leak	65
Assessment of Erenumab Safety and Efficacy in Patients With Migraine With and Without Aura	64
Visualization of Parkinsonian Tongue Tremor on Ultrasonography	64
Clinical Effect of Early vs Late Amyloid Positron Emission Tomography in Memory Clinic Patients	63
IPX203 vs Immediate-Release Carbidopa-Levodopa for the Treatment of Motor Fluctuations in Parkinson Disease	63
Detection of Brain Tau Pathology in Down Syndrome Using Plasma Biomarkers	63
JAMA Neurology Peer Reviewers in 2021	62
Repairing Our View of Dementia	62
The Choreoathetotic Movement of Paroxysmal Nonkinesigenic Dyskinesia	62
Livedo Reticularis—A Presenting Sign of Neuromyelitis Optica Spectrum Disorder	60
Concerns Remain Regarding Ambient NO₂ Exposure and the Risk of Parkinson Disease—Reply	60
Error in Title	60
Burden of Central Nervous System Cancer in the United States, 1990-2021	59
Benefits and Risks of Periconceptional Folic Acid Supplementation—Reply	59
IWG and AA Criteria—Where the Differences Matter—Reply	59
Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple Sclerosis	58
Possible Explanations for Hearing Loss in Parkinson Disease	57
Choosing the Best Antiseizure Medication—Can Artificial Intelligence Help?	57
Benefits and Risks of Periconceptional Folic Acid Supplementation	57
Autism and Parkinsonism—Terminology and Confounding	56
Novel Meningoencephalomyelitis Associated With Vimentin IgG Autoantibodies	53
Reimagining the Treatment of Distal and Medium Vessel Occlusion Strokes	53
Life Expectancy for Patients With Sporadic Creutzfeldt-Jakob Disease	52
SARS-CoV-2 Vaccination and Neuroimmunological Disease	51
Cognitive Behavioral Therapy for Veterans With Comorbid Posttraumatic Headache and Posttraumatic Stress Disorder Symptoms	50
Association of Intensive vs Standard Blood Pressure Control With Cerebral Blood Flow	50
Association Between Acute Myocardial Infarction and Cognition	49
Adverse Childhood Experiences, Toxic Stress, and Trauma-Informed Neurology	49
Coma Prognostication After Acute Brain Injury	49
Alzheimer Disease Blood Biomarkers in Patients With Out-of-Hospital Cardiac Arrest	49
Cerebral Amyloid Angiopathy—How to Translate Updated Diagnostic Criteria for This Multifaceted Disorder to Clinical Practice?	49
Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography	48
Expanding the Prion Paradigm to Include Alzheimer and Parkinson Diseases	48
Addition of Nonauthor Collaborators and a Supplement	48
Monogenic Stroke—Can We Overcome Nature With Nurture?	47
JAMA Neurology	47
A Woman With Eosinophilic Brainstem Meningoencephalitis	47
Views From Both Sides of the White Coat	46
The Perils and Pitfalls of Global Engagement	46
Error in Author Affiliation	46
Comparative Efficacy of Disease-Modifying Treatments for Relapsing Multiple Sclerosis—Variations in Real-World Experience—Reply	46
Errors in Figure 2 and the Short Title	45
How Is the X Chromosome Involved in Alzheimer Disease?	45
Gantenerumab in Dominantly Inherited Alzheimer Disease—Reply	45
Visual Impairment as a Modifiable Risk Factor in Dementia Prevention and Management	44
Transcarotid Artery Revascularization for Stroke Prevention—Multiple Elephants in the Room	44
Structural Inequities for Historically Underserved Communities in the Adoption of Stroke Certification in the United States	43
Efficacy and Safety of Ravulizumab, a Complement C5 Inhibitor, in Adults With Amyotrophic Lateral Sclerosis	43
One-Year Trajectory of Cognitive Changes in Older Survivors of COVID-19 in Wuhan, China	43
A Test of the Alzheimer Disease Framework—Did It Pass?	43
Exome Sequencing and the Identification of New Genes and Shared Mechanisms in Polymicrogyria	42
Chronic Immune Peripheral Nerve Myelinopathies—A Plea for Precision	42
Modern Neurology Training Is Failing Outpatients	42
The End Justifies the Means—A Call for Nuance in the Increasing Nationwide Adoption of Stereoelectroencephalography Over Subdural Electrode Monitoring in the Surgical Evaluation of Intractable Epileps	42
Incidence and Risk Factors of Epilepsy Among Older Adults in the US Medicare Population	42
Discontinuation of First-Line Disease-Modifying Therapy in Patients With Stable Multiple Sclerosis	41
Medical Forecasting—A Skill Set Worthy of Attention	41
TDP-43 Accumulation Within Intramuscular Nerve Bundles of Patients With Amyotrophic Lateral Sclerosis	41
Targeting B Cells and Microglia in Multiple Sclerosis With Bruton Tyrosine Kinase Inhibitors	41
Mitigating the Associations of Kidney Dysfunction With Blood Biomarkers of Alzheimer Disease by Using Phosphorylated Tau to Total Tau Ratios	40
Association of Aortic Stiffness and Pressure Pulsatility With Global Amyloid-β and Regional Tau Burden Among Framingham Heart Study Participants Without Dementia	39
Intravenous Thrombolysis in Patients With Ischemic Stroke and Recent Ingestion of Direct Oral Anticoagulants	39

Association Between Antiseizure Drug Monotherapy and Mortality for Patients With Poststroke Epilepsy	39
Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease	39
Global, Regional, and National Burden of Nontraumatic Subarachnoid Hemorrhage	39
GLP-1 RAs for Idiopathic Intracranial Hypertension—Time for a Trial	39
Bilateral Complete Ophthalmoplegia in a 50-Year-Old Man	38
JAMA Neurology	38
Error in Figures 2 and 3	37
Error in Title	37
A 51-Year-Old Woman With Abnormal Corpus Callosum Signal	37
CT Perfusion Imaging After Selection for Late-Window Endovascular Stroke Treatment	37
Acute Ischemic Stroke Care Quality Improvement	37
Multimodal Neuroimaging of Intimal Flap in a Basilar Artery Dissection	36
JAMA Neurology	36
Discussion on the Application of Rapid Immunoblot Assay for AQP4-IgG Detection	35
Venture Capital Investment in Neurology Companies	35
Error in Open Access Status	35
Targeting Sleep and Circadian Function in the Prevention of Alzheimer Disease	35
Transient Focal Neurological Events in Cerebral Amyloid Angiopathy and the Long-term Risk of Intracerebral Hemorrhage and Death	34
White Matter Tract Density Index Prediction Model of Overall Survival in Glioblastoma	34
An Acetylcholine M₁ Receptor–Positive Allosteric Modulator (TAK-071) in Parkinson Disease With Cognitive Impairment	34
2024 Diagnostic Criteria for Multiple Sclerosis—A Unified Approach	34
Advocating for Demonstration of Disease Modification—Have We Been Approaching Clinical Trials in Early Alzheimer Disease Incorrectly?	33
Risks of Expanded Medicare Coverage of Carotid Artery Stenting	33
Directly Isolated Allogeneic Virus–Specific T Cells in Progressive Multifocal Leukoencephalopathy	33
Cerebrospinal Fluid Biomarkers for Alzheimer Disease Among Patients With Dementia	33
Physical Frailty, Genetic Predisposition, and Incident Parkinson Disease	32
Neurologic Complications of Smallpox and Monkeypox	32
Prevalence and Clinical Implications of a β-Amyloid–Negative, Tau-Positive Cerebrospinal Fluid Biomarker Profile in Alzheimer Disease	32
Immediate- or Delayed-Intensive Statin in Acute Cerebral Ischemia	32
Efficacy and Safety of Erenumab for Nonopioid Medication Overuse Headache in Chronic Migraine	32
Recurrent Ischemic Stroke in Patients With Atrial Fibrillation While Receiving Oral Anticoagulants	32
Endovascular Thrombectomy Treatment Effect in Direct vs Transferred Patients With Large Ischemic Strokes	32
Batoclimab vs Placebo for Generalized Myasthenia Gravis	31
Development and Validation of a Deep Learning Model for Predicting Treatment Response in Patients With Newly Diagnosed Epilepsy	31
Therapeutic Management During Pregnancy and Relapse Risk in Women With Multiple Sclerosis	31
Risk of Stroke, Death, and Myocardial Infarction Following Transcarotid Artery Revascularization vs Carotid Endarterectomy in Patients With Standard Surgical Risk	30
E-Cigarettes and Stroke Risk—Present Uncertainties and Future Directions	30
Genome Sequencing After Exome Sequencing in Pediatric Epilepsy	30
Multisite Skin Biopsies vs Cerebrospinal Fluid for Prion Seeding Activity in the Diagnosis of Prion Diseases	30
Risk Factors for Young-Onset Dementia in the UK Biobank	30
ApoE4 and Connectivity-Mediated Spreading of Tau Pathology at Lower Amyloid Levels	30
Error in Methods	30
Entering Medicine as a Physician and a Patient	29
A Funeral for a Neurologist	29
Association Between Use of Angiotensin Receptor Blockers and Incidence of Epilepsy in Patients With Hypertension—Reply	29
Inducers and Cardiovascular Risk—Potential Role for Lowered Drug Exposure	29
Paused—A Residency Interrupted	29
Light Reading—The Gravity of Postoperative Care	29
Remembering the Physician’s Humanity—Physicians Are Humans Too	28
A New Dystonia Phenotype in Wilson Disease	28
JAMA Neurology Editorial Fellowship	28
Neuro-Advocacy—Professionalism in Action	28
What Should the Goals Be for Diverse Recruitment in Alzheimer Clinical Trials?	28
Association of Tourette Syndrome and Chronic Tic Disorder With Violent Assault and Criminal Convictions	28
Rethinking the Menopause Transition and Multiple Sclerosis Progression	28
Quality Improvement Intervention for Reducing Acute Treatment Times in Ischemic Stroke	27
Intramedullary Hemorrhage Causing Quadriplegia in the Setting of a Type B Aortic Dissection	27
Pattern of Recurrent Nontraumatic Intracerebral Hemorrhage—Reply	27
Embedded Human Closed-Loop Deep Brain Stimulation for Tourette Syndrome	27
Clinical Utility of Tau Positron Emission Tomography in the Diagnostic Workup of Patients With Cognitive Symptoms	27
Butter Yellow—A Soft Hue With Neurological Implications	27
Postmortem Assessment of Olfactory Tissue Degeneration and Microvasculopathy in Patients With COVID-19	27
Kelch-Like Protein 11 Antibody-Associated Paraneoplastic Encephalitis	26
Distinguishing Frontotemporal Lobar Degeneration Tau From TDP-43 Using Plasma Biomarkers	26
Safety and Efficacy of Staged, Bilateral Focused Ultrasound Thalamotomy in Essential Tremor	26
Effect of Irrigation Fluid Temperature on Recurrence in the Evacuation of Chronic Subdural Hematoma	26
Gene Therapy vs Cochlear Implantation in Restoring Hearing Function and Speech Perception for Individuals With Congenital Deafness	26
Error in Figure 1	25
Lecanemab Treatment in a Specialty Memory Clinic	25
Commentary on Long-term Effectiveness of Adjuvant Treatment in Parkinson Disease—Reply	25
Cholinesterase Inhibitors for Treatment of Psychotic Symptoms in Alzheimer Disease and Parkinson Disease	25
Error in Figure 2B	25
Risk of Inflammatory Central Nervous System Diseases After Tumor Necrosis Factor–Inhibitor Treatment for Autoimmune Diseases	25
Bilateral Calcification of the Meckel Cave Causing Hemicrania Continua	25
Error in Title	25
Gadolinium-Enhanced Aneurysm Wall Imaging and Risk of Intracranial Aneurysm Growth or Rupture	24
Levodopa Content of Mucuna pruriens Supplements in the NIH Dietary Supplement Label Database	24
Direct-Acting Oral Anticoagulants and Antiseizure Medications for Atrial Fibrillation and Epilepsy and Risk of Thromboembolic Events	24
Risk Factors and Prognosis of Early Posttraumatic Seizures in Moderate to Severe Traumatic Brain Injury	24
Error in Figures	23
How SAFE Is Real-world Use of Spinal Cord Stimulation Therapy for Chronic Pain?	23
Trends in AVM-Associated Intracranial Hemorrhage in the United States, 2000-2019	23
JAMA Neurology	23
Effect of Bypassing the Closest Stroke Center in Patients with Intracerebral Hemorrhage	23
Central Retinal Artery Occlusion With Cilioretinal Artery Sparing After Semaglutide Injection	23
Research Criteria for the Behavioral Variant of Alzheimer Disease	23
Combined Physiotherapy and Cognitive Behavioral Therapy for Functional Movement Disorders	23
Higher Educational Attainment and Accelerated Tau Accumulation in Alzheimer Disease	23
Anticoagulation in ESUS—Back From the Dead?	23
Iatrogenic Cerebrospinal Fluid–Venous Fistula	23
Error in Title	23
Errors in Results in Abstract and Text and in Table 1	22
Oncogenic Pathways Provide Clue to the Etiology of Human Mesial Temporal Lobe Epilepsy	22
JAMA Neurology—The Year in Review, 2023	22
Sex Differences in Case-Fatality Rates of Stroke—Reply	22